{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:56:29Z","timestamp":1792245389670,"version":"4.4.0"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T00:00:00Z","timestamp":1552435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Tissue tumor mutational burden (TMB) has emerged as a potential biomarker predicting response to anti-programmed cell death-1 protein receptor (PD-1)\/programmed cell death-1 protein ligand (PD-L1) therapy, but few studies have explored using circulating tumor DNA (ctDNA) TMB in non-small cell lung cancer (NSCLC).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>A total of 136 patients with NSCLC with ctDNA testing were retrospectively evaluated from a single institution, along with a validation cohort from a second institution. ctDNA TMB was derived using the number of detected mutations over the DNA sequencing length.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Higher ctDNA TMB was significantly correlated with smoking history (p\u2009&amp;lt;\u2009.05, chi-squared test). Among patients treated with immune checkpoint inhibitors (n\u2009=\u200920), higher ctDNA TMB was significantly correlated with shorter progressive free survival (PFS) and overall survival (OS; 45 vs. 355 days; hazard ratio [HR], 5.6; 95% confidence interval [CI], 1.3\u201324.6; p\u2009&amp;lt;\u2009.01, and OS 106 days vs. not reached; HR, 6.0; 95% CI, 1.3\u201327.1; p\u2009&amp;lt;\u2009.01, respectively). In a small independent validation cohort (n\u2009=\u200912), there was a nonsignificant numerical difference for higher ctDNA TMB predicting shorter OS but not PFS. ctDNA TMB was not correlated with RECIST tumor burden estimation in the subset of patients treated with immune checkpoint blockade.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The findings indicate that higher ctDNA TMB, at the current commercial sequencing length, reflects worse clinical outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0433","type":"journal-article","created":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T19:39:07Z","timestamp":1552505947000},"page":"820-828","source":"Crossref","is-referenced-by-count":99,"title":["Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer"],"prefix":"10.1093","volume":"24","author":[{"given":"Young Kwang","family":"Chae","sequence":"first","affiliation":[{"name":"Developmental Therapeutics Program of Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"},{"name":"Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarita","family":"Agte","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas I.","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade T.","family":"Iams","sequence":"additional","affiliation":[{"name":"Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo R.","family":"Cruz","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Program of Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keerthi","family":"Tamragouri","sequence":"additional","affiliation":[{"name":"Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyunghoon","family":"Rhee","sequence":"additional","affiliation":[{"name":"Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Mohindra","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Program of Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Villaflor","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Program of Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"},{"name":"Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wungki","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Lopes","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J.","family":"Giles","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Program of Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"},{"name":"Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,3,13]]},"reference":[{"key":"2021122507121034000_R1","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122507121034000_R2","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122507121034000_R3","first-page":"1659","article-title":"DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells","volume":"61","author":"Jahr","year":"2001","journal-title":"Cancer Res"},{"key":"2021122507121034000_R4","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature12065","article-title":"Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA","volume":"497","author":"Murtaza","year":"2013","journal-title":"Nature"},{"key":"2021122507121034000_R5","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1158\/1078-0432.CCR-16-0318","article-title":"Use of liquid biopsies in clinical oncology: Pilot experience in 168 patients","volume":"22","author":"Schwaederle","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2021122507121034000_R6","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1158\/2159-8290.CD-15-0274","article-title":"Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas","volume":"5","author":"Zill","year":"2015","journal-title":"Cancer Discov"},{"key":"2021122507121034000_R7","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1158\/1078-0432.CCR-14-2594","article-title":"Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy","volume":"21","author":"Mok","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2021122507121034000_R8","doi-asserted-by":"crossref","first-page":"40360","DOI":"10.18632\/oncotarget.5465","article-title":"Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients","volume":"6","author":"Kim","year":"2015","journal-title":"Oncotarget"},{"key":"2021122507121034000_R9","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1158\/1078-0432.CCR-16-1231","article-title":"Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA","volume":"22","author":"Thompson","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2021122507121034000_R10","doi-asserted-by":"crossref","first-page":"65364","DOI":"10.18632\/oncotarget.11692","article-title":"Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA","volume":"7","author":"Chae","year":"2016","journal-title":"Oncotarget"},{"key":"2021122507121034000_R11","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jamaoncol.2016.4983","article-title":"Comparison of 2 commercially available next-generation sequencing platforms in oncology","volume":"3","author":"Kuderer","year":"2016","journal-title":"JAMA Oncol"},{"key":"2021122507121034000_R12","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1158\/1535-7163.MCT-17-0061","article-title":"Concordance of genomic alterations by next-generation sequencing in tumor tissue versus circulating tumor DNA in breast cancer","volume":"16","author":"Chae","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"2021122507121034000_R13","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.cllc.2016.03.011","article-title":"Biomarkers for PD-1\/PD-L1 blockade therapy in non-small-cell lung cancer: Is PD-L1 expression a good marker for patient selection?","volume":"17","author":"Chae","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"2021122507121034000_R14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40425-016-0107-3","article-title":"Novel technologies and emerging biomarkers for personalized cancer immunotherapy","volume":"4","author":"Yuan","year":"2016","journal-title":"J Immunother Cancer"},{"key":"2021122507121034000_R15","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2012.08.024","article-title":"Genomic landscape of non-small cell lung cancer in smokers and never-smokers","volume":"150","author":"Govindan","year":"2012","journal-title":"Cell"},{"key":"2021122507121034000_R16","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nature11071","article-title":"Melanoma genome sequencing reveals frequent PREX2 mutations","volume":"485","author":"Berger","year":"2012","journal-title":"Nature"},{"key":"2021122507121034000_R17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"2021122507121034000_R18","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1101\/gr.165985.113","article-title":"Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival","volume":"24","author":"Brown","year":"2014","journal-title":"Genome Res"},{"key":"2021122507121034000_R19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"2021122507121034000_R20","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/2326-6066.CIR-16-0143","article-title":"Targeted next generation sequencing identifies markers of response to PD-1 blockade","volume":"4","author":"Johnson","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"2021122507121034000_R21","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"key":"2021122507121034000_R22","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"2021122507121034000_R23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"2021122507121034000_R24","doi-asserted-by":"crossref","first-page":"34221","DOI":"10.18632\/oncotarget.5950","article-title":"Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice","volume":"6","author":"Campesato","year":"2015","journal-title":"Oncotarget"},{"key":"2021122507121034000_R25","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.11537","volume-title":"Association of tumor mutational burden (TMB) with DNA repair mutations and response to anti-PD-1\/PD-L1 therapy in non-small cell lung cancer (NSCLC)","author":"Davis","year":"2017"},{"key":"2021122507121034000_R26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2021122507121034000_R27","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2021122507121034000_R28","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1158\/1078-0432.CCR-17-3831","article-title":"Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies","volume":"24","author":"Odegaard","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2021122507121034000_R29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140712","article-title":"Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA","volume":"10","author":"Lanman","year":"2015","journal-title":"PLoS One"},{"key":"2021122507121034000_R30","doi-asserted-by":"crossref","first-page":"23312","DOI":"10.18632\/oncotarget.8196","article-title":"Genomic landscape of DNA repair genes in cancer","volume":"7","author":"Chae","year":"2016","journal-title":"Oncotarget"},{"key":"2021122507121034000_R31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1200\/JCO.2012.43.1718","article-title":"Use of research biopsies in clinical trials: Are risks and benefits adequately discussed?","volume":"31","author":"Overman","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122507121034000_R32","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"2021122507121034000_R33","doi-asserted-by":"crossref","first-page":"224ra224","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"2021122507121034000_R34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002198","article-title":"Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: A retrospective study","volume":"13","author":"Parkinson","year":"2016","journal-title":"PLoS Med"},{"key":"2021122507121034000_R35","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-017-4257-x","article-title":"Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer","volume":"164","author":"Maxwell","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 15","key":"2021122507121034000_R36","article-title":"Comparison of tumor mutational burden (TMB) across tumor tissue and circulating tumor DNA (ctDNA)","volume":"35","author":"Davis","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122507121034000_R37","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.1158\/1078-0432.CCR-17-1439","article-title":"Hypermutated circulating tumor DNA: Correlation with response to checkpoint inhibitor-based immunotherapy","volume":"23","author":"Khagi","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2021122507121034000_R38","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med"},{"key":"2021122507121034000_R39","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1158\/1078-0432.CCR-11-0564","article-title":"Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan","volume":"18","author":"Spindler","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021122507121034000_R40","doi-asserted-by":"crossref","first-page":"13195","DOI":"10.18632\/oncotarget.14490","article-title":"Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in nsclc patients treated with EGFR-TKIs","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"2021122507121034000_R41","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1158\/1078-0432.CCR-16-0806","article-title":"Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker","volume":"23","author":"Pietrasz","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2021122507121034000_R42","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/annonc\/mdv177","article-title":"Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer","volume":"26","author":"Tie","year":"2015","journal-title":"Ann Oncol"},{"key":"2021122507121034000_R43","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2017-582","volume-title":"Circulating tumor DNA (ctDNA) variant allele frequencies are reduced in responders to durvalumab and low baseline variant allele frequencies are associated with improved overall survival in NSCLC patients","author":"Kuziora","year":"2017"},{"key":"2021122507121034000_R44","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40425-014-0042-0","article-title":"Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade","volume":"2","author":"Lipson","year":"2014","journal-title":"J Immunother Cancer"},{"key":"2021122507121034000_R45","doi-asserted-by":"crossref","first-page":"42008","DOI":"10.18632\/oncotarget.5788","article-title":"Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma","volume":"6","author":"Gray","year":"2015","journal-title":"Oncotarget"},{"key":"2021122507121034000_R46","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"2021122507121034000_R47","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nature12625","article-title":"The causes and consequences of genetic heterogeneity in cancer evolution","volume":"501","author":"Burrell","year":"2013","journal-title":"Nature"},{"key":"2021122507121034000_R48","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the evolution of non-small-cell lung cancer","volume":"376","author":"Jamal-Hanjani","year":"2017","journal-title":"N Engl J Med"},{"key":"2021122507121034000_R49","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122507121034000_R50","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","article-title":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","volume":"24","author":"Gandara","year":"2018","journal-title":"Nat Med"},{"key":"2021122507121034000_R51","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat Med"},{"key":"2021122507121034000_R52","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0433","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0433","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/6\/820\/41918024\/oncolo_24_6_820.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/6\/820\/41918024\/oncolo_24_6_820.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T07:12:41Z","timestamp":1640416361000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/6\/820\/6439485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,13]]},"references-count":52,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,3,13]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0433","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6,1]]},"published":{"date-parts":[[2019,3,13]]}}}